Drugs, hERG and sudden death.

Early recognition of potential QT/TdP liability is now an essential component of the drug discovery/drug development program. The hERG assay is an indispensable step and a high-quality assay must accompany any investigational new drug (IND) application. While it is the gold standard at present, the hERG assay is too labor-intensive and too low throughput to be used as a screen early in the discovery/development process. A variety of indirect high throughput screens have been used.

[1]  A. Brown,et al.  A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.

[2]  A J Moss,et al.  Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. , 1993, The American journal of cardiology.

[3]  G. Gintant,et al.  The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.

[4]  A. Brown,et al.  HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. , 1996, Circulation.

[5]  Qiuming Gong,et al.  Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, American journal of physiology. Heart and circulatory physiology.

[6]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[7]  James Kramer,et al.  Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs , 2001 .

[8]  A. Brown,et al.  Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG , 2003, Circulation research.

[9]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[10]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.